Short Interest in Evotec SE (NASDAQ:EVO) Rises By 89.9%

Evotec SE (NASDAQ:EVO) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 766,200 shares, a growth of 89.9% from the December 15th total of 403,500 shares. Based on an average trading volume of 232,100 shares, the days-to-cover ratio is presently 3.3 days. Currently, 0.3% of the company’s stock are sold short.

Institutional Investors Weigh In On Evotec

Institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP lifted its stake in shares of Evotec by 29.7% during the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company’s stock worth $9,616,000 after acquiring an additional 602,858 shares during the last quarter. Novo Holdings A S bought a new stake in shares of Evotec during the second quarter worth $71,183,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Evotec during the second quarter worth $87,000. DCF Advisers LLC boosted its stake in shares of Evotec by 140.5% during the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after purchasing an additional 67,156 shares during the period. Finally, Mediolanum International Funds Ltd bought a new position in shares of Evotec in the third quarter worth about $512,000. 5.81% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

EVO has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Evotec in a research note on Thursday, November 7th. Jefferies Financial Group lowered shares of Evotec from a “buy” rating to a “hold” rating and cut their target price for the stock from $8.70 to $3.80 in a research report on Monday, October 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Evotec presently has a consensus rating of “Hold” and an average target price of $5.93.

Evotec Stock Performance

Shares of EVO stock traded down $0.10 during trading hours on Tuesday, hitting $4.08. The stock had a trading volume of 49,513 shares, compared to its average volume of 59,552. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43. Evotec has a one year low of $2.85 and a one year high of $8.39. The stock’s 50-day moving average price is $4.63 and its two-hundred day moving average price is $4.12.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.